Treatment Updates

March 27, 2018: Adult and Adolescent ARV Guideline Panel Issues Statement on Bictegravir

The Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV panel issued a statement on the use of bictegravir (BIC). A summary of the statement is below.

BIC/TAF/FTC is an effective and well-tolerated INSTI-based regimen for initial therapy in adults with HIV, with efficacy that is noninferior to DTG/ABC/3TC and DTG plus TAF/FTC for up to 48 weeks. On the basis of these clinical trial results, the Panel classifies BIC/TAF/FTC as one of the Recommended Initial Regimens for Most Adults with HIV (AI).

January 2017: Updated HIV Drug Interaction Tools

Printable Drug Interaction Chart

Online Drug Interaction Tool

January, 2017: HIV Drug Resistance Mutations

July 14, 2016: Updated DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

August 15, 2014: Increase in Early Syphilis Infections Statewide: North Carolina Department of Health and Human Services Health Alert